Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Tempest Therapeutics

27/03/2023 22:02

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 76 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tempest Therapeutics Inc's reported EPS for the quarter
was a
loss of 63 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Tempest Therapeutics Inc shares had risen by 18.3% this
quarter.
    * The company reported a quarterly loss of $9.1 million.
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $8.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 27 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.76          -0.63          Beat
 Sep. 30 2022      -0.80          -0.66          Beat
 Jun. 30 2022      -0.92          -0.79          Beat
 Mar. 31 2022      -1.12          -1.18          Missed